Treatment
PD-1/PD-L1 inhibitor clinical trials
We’re tracking 33 recruiting studies that include PD-1/PD-L1 inhibitor, each written for real people, not researchers, below.
Recruiting studies
- NCT06099821RecruitingPhase 2
KN046 plus targeted pills for resistant MSI-H digestive cancers
This trial tests two types of targeted therapy pills (Regorafenib or Apatinib) combined with a new immunotherapy drug (KN046). It is for people with MSI-H or dMMR digestive system cancers that have stopped responding to standard immunotherapy.
BeijingAges 18 years+ - NCT06826079RecruitingPhase 2/Phase 3
Sorbitol plus chemo and immunotherapy for advanced gastric cancer
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Wuhan, HubeiAges 18–70 - NCT07332247RecruitingPhase 2
Immunotherapy plus chemo then immediate vs selective re-radiation for advanced recurrent NPC
This trial is for people with nasopharyngeal cancer that has come back in the same area. It tests whether giving additional radiation right after chemo plus immunotherapy works better than waiting to see if more radiation is needed later.
Guangzhou, GuangdongAges 18–70 - NCT07387198RecruitingPhase 2
Testing cemiplimab before surgery for Merkel cell carcinoma
This trial tests whether giving the immunotherapy drug cemiplimab before surgery can improve outcomes for people with stage I or II Merkel cell carcinoma. If you qualify, you would receive cemiplimab before your sentinel lymph node biopsy.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT07002346RecruitingPhase 3
Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Wuhan, HubeiAges 18–75 - NCT06939855RecruitingPhase 2
QL1706 for advanced bone and soft tissue sarcoma
This trial tests an experimental drug called QL1706 for people with advanced sarcoma (a type of cancer that starts in bones or soft tissues like muscle or fat) that cannot be removed by surgery or has spread. The goal is to see if QL1706 can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06261125RecruitingPhase 2
SBRT plus immunotherapy and targeted drug for liver cancer
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Guangzhou, GuangdongAges 18–75 - NCT06501391RecruitingPhase 2
Brain radiation plus chemo-immunotherapy for untreated NSCLC with stable brain metastases
This trial tests whether combining brain radiation with chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the brain but has not yet been treated. It is for those whose tumors do not have certain gene mutations (EGFR, ALK, ROS1).
ShanghaiAges 18 years+ - NCT05142189RecruitingPhase 1
Testing BNT116 for advanced non-small cell lung cancer
This trial tests an experimental immunotherapy called BNT116, given alone or with other drugs, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if it is safe and if it can help shrink tumors.
Lexington, KentuckyAges 18 years+
Common questions
- Are there clinical trials studying PD-1/PD-L1 inhibitor?
- Yes. Clin2 currently lists 33 recruiting studies that include PD-1/PD-L1 inhibitor, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a PD-1/PD-L1 inhibitor trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is PD-1/PD-L1 inhibitor an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether PD-1/PD-L1 inhibitor or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.